TANG KEVIN purchased $350K of BOLD (indirect holdings)

TANG KEVIN purchased 149,474 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.34 ($2.33–$2.37, $0.35M total) across 4 trades over 2026-10-16 to 2026-10-20. Filed jointly with TANG CAPITAL MANAGEMENT LLC (10% owner).

Original reporting
SEC EDGAR · TANG KEVIN, TANG CAPITAL MANAGEMENT LLC
Published Oct 20, 2026, 9:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 9:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BOLD
Bullish
medium confidence
Mentioned
$BOLD
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLDBullishLow
01

Why it matters

The disclosed purchase may modestly lift BOLD's share price as traders interpret insider confidence.

02

Market read

A modest insider buy in a small-cap biotech, likely to generate limited short‑term price movement.

03

What to watch

Potential upcoming clinical data releases or financing events not disclosed in the filing.

Relevance 5/10Novelty 5/10Timing: post‑filing today

Background

Form 4 filings provide the first public disclosure of insider trades, offering insight into insider sentiment.

Company-level read

Ticker impact

$BOLDBullishMedium confidence
Context

SEC Form 4 shows insider Tang Kevin buying ~150k shares for $350K, increasing his stake to ~2.99M shares.

Expected impact

likely upward pressure as the market prices in insider confidence

Evidence & confidence

Insider purchases by large shareholders often precede positive sentiment, especially when the stake is sizable and the transaction is disclosed promptly.

Market effects

Minimal; reflects confidence in Boundless Bio's pipeline but does not affect sector broadly.

None

Limited to investors tracking biotech insider activity.

Counterpoint

The purchase could be a routine portfolio rebalancing rather than a bullish signal.

Key entities

  • Boundless Bio, Inc.

    Biotech firm (ticker BOLD) subject of the insider purchase.

  • Tang Kevin

    10% owner executing the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BOLDMed

Boundless Bio 3Q 2026: EPS ($0.23) — 10-Q Summary

Boundless Bio reported a 61.4% narrower net loss of $5.36M in Q3 2026, with EPS at ($0.23). The reduction was driven by lower clinical-trial spending, reduced facilities, and personnel costs. The company also announced a 75% workforce reduction and expects a merger with Serapha Bio to close in Q4 2026, with a pre-closing dividend of $44M-$48M.